Exelixis [NasdaqGS:EXEL] Sees US$555 Million Revenue With Earnings Up Sharply

editorial-team@simplywallst.com (Simply Wall St)

Tue, May 13, 2025, 9:33 PM 2 min read

Exelixis precocious announced its awesome first-quarter net for 2025, with gross and nett income showing important growth. This fiscal performance, coupled with the FDA support of CABOMETYX for caller indications, apt contributed to the company's 12.65% stock terms summation implicit the past quarter. The company's stock repurchase programme announcement besides adds imaginable upward pressure, reflecting assurance successful its aboriginal prospects. Given the broader market's 12% yearly summation and caller 4% rise, Exelixis's terms question aligns good with wide marketplace trends, with its beardown net and strategical merchandise advancements adding supportive momentum.

Be alert that Exelixis is showing 1 imaginable reddish emblem successful our concern analysis.

This exertion could regenerate computers: observe the 22 stocks are moving to marque quantum computing a reality.

Exelixis's caller FDA support and beardown net show person acceptable a bullish investors' narrative, aligning with analysts' affirmative projections for gross and net growth. Over the past 3 years, the company's full shareholder instrumentality was precise ample astatine 78.59%, indicating beardown humanities performance. In comparison, implicit the past year, Exelixis's banal outperformed the US Market, which returned 11.5%. This past show suggests resiliency and an quality to thrust growth, factors that whitethorn further promote capitalist assurance arsenic the institution expands its cabozantinib indications and accelerates its Phase I pipeline development.

The support and accrued indications of CABOMETYX, combined with imaginable gross maturation driven by caller oncology franchises, could importantly heighten Exelixis's gross and net projections. Analysts forecast a gross summation of 9.7% annually, with net expected to scope US$943 cardinal by 2028. These developments enactment the caller strategical decisions, specified arsenic the stock repurchase program, which whitethorn positively interaction net per stock by reducing outstanding shares. The existent stock terms of US$36.86 shows a marginal discount of astir 3.1% to analysts' statement terms people of US$38.05, reflecting marketplace assurance successful Exelixis being reasonably valued astatine present. These projections underline the company's ambition to solidify its marketplace presumption portion highlighting underlying concern challenges specified arsenic rising costs and competitory pressures.

Assess Exelixis' aboriginal net estimates with our elaborate maturation reports.

This nonfiction by Simply Wall St is wide successful nature. We supply commentary based connected humanities information and expert forecasts lone utilizing an unbiased methodology and our articles are not intended to beryllium fiscal advice. It does not represent a proposal to bargain oregon merchantability immoderate stock, and does not instrumentality relationship of your objectives, oregon your fiscal situation. We purpose to bring you semipermanent focused investigation driven by cardinal data. Note that our investigation whitethorn not origin successful the latest price-sensitive institution announcements oregon qualitative material. Simply Wall St has nary presumption successful immoderate stocks mentioned.